Thomas Griffith
Thomas Griffith
Verified email at
Cited by
Cited by
Tumoricidal activity of tumor necrosis factor–related apoptosis–inducing ligand in vivo
H Walczak, RE Miller, K Ariail, B Gliniak, TS Griffith, M Kubin, W Chin, ...
Nature medicine 5 (2), 157-163, 1999
Fas ligand-induced apoptosis as a mechanism of immune privilege
TS Griffith, T Brunner, SM Fletcher, DR Green, TA Ferguson
Science 270 (5239), 1189-1192, 1995
Intracellular regulation of TRAIL-induced apoptosis in human melanoma cells
TS Griffith, WA Chin, GC Jackson, DH Lynch, MZ Kubin
The Journal of Immunology 161 (6), 2833-2840, 1998
CD4+ T-cell help controls CD8+ T-cell memory via TRAIL-mediated activation-induced cell death
EM Janssen, NM Droin, EE Lemmens, MJ Pinkoski, SJ Bensinger, ...
Nature 434 (7029), 88-93, 2005
TRAIL: a molecule with multiple receptors and control mechanisms
TS Griffith, DH Lynch
Current opinion in immunology 10 (5), 559-563, 1998
Monocyte-mediated tumoricidal activity via the tumor necrosis factor–related cytokine, TRAIL
TS Griffith, SR Wiley, MZ Kubin, LM Sedger, CR Maliszewski, NA Fanger
The Journal of experimental medicine 189 (8), 1343-1354, 1999
Human dendritic cells mediate cellular apoptosis via tumor necrosis factor–related apoptosis-inducing ligand (TRAIL)
NA Fanger, CR Maliszewski, K Schooley, TS Griffith
The Journal of experimental medicine 190 (8), 1155-1164, 1999
CD95 ligand (FasL)-induced apoptosis is necessary for corneal allograft survival.
PM Stuart, TS Griffith, N Usui, J Pepose, X Yu, TA Ferguson
The Journal of clinical investigation 99 (3), 396-402, 1997
CD95-induced apoptosis of lymphocytes in an immune privileged site induces immunological tolerance
TS Griffith, X Yu, JM Herndon, DR Green, TA Ferguson
Immunity 5 (1), 7-16, 1996
Induction of glioblastoma apoptosis using neural stem cell-mediated delivery of tumor necrosis factor-related apoptosis-inducing ligand
M Ehtesham, P Kabos, MAR Gutierrez, NHC Chung, TS Griffith, KL Black, ...
Cancer research 62 (24), 7170-7174, 2002
Intravascular staining for discrimination of vascular and tissue leukocytes
KG Anderson, K Mayer-Barber, H Sung, L Beura, BR James, JJ Taylor, ...
Nature protocols 9 (1), 209-222, 2014
The role of FasL-induced apoptosis in immune privilege
TS Griffith, TA Ferguson
Immunology today 18 (5), 240-244, 1997
Functional analysis of TRAIL receptors using monoclonal antibodies
TS Griffith, CT Rauch, PJ Smolak, JY Waugh, N Boiani, DH Lynch, ...
The Journal of Immunology 162 (5), 2597-2605, 1999
Adenoviral-mediated transfer of the TNF-related apoptosis-inducing ligand/Apo-2 ligand gene induces tumor cell apoptosis
TS Griffith, RD Anderson, BL Davidson, RD Williams, TL Ratliff
The Journal of Immunology 165 (5), 2886-2894, 2000
Antiinflammatory effects of CD95 ligand (FasL)-induced apoptosis
Y Gao, JM Herndon, H Zhang, TS Griffith, TA Ferguson
The Journal of experimental medicine 188 (5), 887-896, 1998
TNF-related apoptosis-inducing ligand (TRAIL): a new path to anti-cancer therapies
PA Holoch, TS Griffith
European journal of pharmacology 625 (1-3), 63-72, 2009
Uptake of apoptotic antigen-coupled cells by lymphoid dendritic cells and cross-priming of CD8+ T cells produce active immune unresponsiveness
TA Ferguson, J Herndon, B Elzey, TS Griffith, S Schoenberger, DR Green
The Journal of Immunology 168 (11), 5589-5595, 2002
CD8 T cells utilize TRAIL to control influenza virus infection
EL Brincks, A Katewa, TA Kucaba, TS Griffith, KL Legge
The Journal of Immunology 181 (7), 4918-4925, 2008
Cell cycle-dependent regulation of FLIP levels and susceptibility to Fas-mediated apoptosis
A Algeciras-Schimnich, TS Griffith, DH Lynch, CV Paya
The Journal of Immunology 162 (9), 5205-5211, 1999
A vision of cell death: insights into immune privilege
TA Ferguson, TS Griffith
Immunological reviews 156 (1), 167-184, 1997
The system can't perform the operation now. Try again later.
Articles 1–20